Drug intelligence / Profile preview

Haemodoc-Z

Development stage: Unknown
Lead developer: Docventures
Modality: Small Molecules
Administration: Oral

Overview

Haemodoc-Z is an oral nutritional supplement developed and marketed by Docventures Pharmaceuticals. It is a combination product containing folic acid (Vitamin B9) and zinc. Folic acid is a critical cofactor in the synthesis of DNA, RNA, and amino acids, and is essential for the production of healthy red blood cells, making it effective for treating megaloblastic anemia and preventing neural tube defects. Zinc is an essential trace element that supports immune function, protein synthesis, and cellular metabolism by acting as a cofactor for numerous enzymes. The product is primarily indicated for the treatment of anemia resulting from nutritional deficiencies and as a general dietary supplement to support overall health and recovery.

Brand names: Haemodoc-ZHAEMODOC Z

Targets

DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on Haemodoc-Z.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Haemodoc-Z.

Explore the full profile